Annual report pursuant to Section 13 and 15(d)

Organization and Basis of Presentation (Details Narrative)

v3.21.1
Organization and Basis of Presentation (Details Narrative) - USD ($)
1 Months Ended
Mar. 02, 2021
Nov. 30, 2020
Nov. 18, 2020
Jan. 18, 2021
Dec. 31, 2020
Dec. 31, 2019
Cash and cash equivalents         $ 5,069,266 $ 2,598,864
Proceeds from issuance of common stock and warrants   $ 4,591,349        
Common Stock [Member]            
Reverse stock split     1-for-6 reverse split      
Subsequent Event [Member] | Common Stock [Member]            
Estimated gross proceeds from offering of shares $ 3,690,000          
Subsequent Event [Member] | Phase 1b Clinical Trial [Member] | Minimum [Member]            
Estimated cost of clinical trial       $ 2,500,000    
Subsequent Event [Member] | Phase 1b Clinical Trial [Member] | Maximum [Member]            
Estimated cost of clinical trial       $ 2,900,000